Sientra implants not at risk of FDA temporary moratorium, ban: Stephens

After attending the first day of the FDA’s Plastic Surgery Devices Advisory Committee Meeting, Stephens analyst Chris Cooley said it is his view that Sientra’s textured silicone gel implants are not at risk of an FDA temporary moratorium or ban. The panel’s conclusion that all textured implants are not equal also makes a category ban on textured implants unlikely, Cooley added. He remains comfortable with his “modestly above consensus” revenue estimates for Sientra and reiterates an Overweight rating and $26 price target on the stock.
https://thefly.com/landingPageNews.php?id=2884273